Skip to main content

ELUVIA™

Drug-Eluting Vascular Stent System

play icon
The Challenge
play icon
The Solution
play icon
The Heritage
play icon
The Breakthrough
play icon
The Data
play icon
The Challenge
play icon
The Solution
play icon
The Heritage
play icon
The Breakthrough
play icon
The Data
Hear what physicians have to say about the challenges of treating the SFA and how drug-eluting vascular stents may help improve patient outcomes.
Physicians talk about the importance of drug-eluting stents in complex lesions and how the Eluvia Drug-Eluting Stent is designed to deliver controlled, localized, low-dose amorphous paclitaxel to target lesions.
See how over a decade of research helped Eluvia engineers develop the first drug-eluting stent for the SFA designed to sustain drug release when restenosis is most likely.
Physicians discuss the tuned paclitaxel elution profile of the Eluvia Drug-Eluting Stent and how the stent has demonstrated unprecedented efficacy data in patients with peripheral artery disease (PAD).
See what physicians are saying about the unprecedented clinical outcomes for the Eluvia Drug-Eluting Stent, including two-year primary patency and TLR rates.

Eluvia provides consistent, durable outcomes in challenging SFA disease and features a polymer design for controlled drug release.

Read the Full Boston Scientific Response to FDA Update About Use of Paclitaxel-Coated Devices to Treat Peripheral Arterial Disease Indications, Safety, and Warnings
Explore Drug-Eluting Technologies
Eluvia Product Brochure.

Eluvia Product Brochure

 Join Our Drug Eluting Community.

Join Our Drug Eluting Community

 Resource Download Center.

Resource Download Center

Product Details

Exceptional Outcomes in Complex Lesions

In the world’s first head-to-head DES SFA trial1, Eluvia demonstrated the highest ever reported 2-year Kaplan-Meier primary Patency of 83%2 and showed low 2-year TLR in patients with long lesions, diabetes, CTOs, and severe/moderate calcium. 

As the only device using polymer to elute drug for PAD, Eluvia features the lowest drug dose with the fewest downstream particulates3, leaving no paclitaxel in the bloodstream at 30 minutes post implant.4

Available now in 150mm length. Ask your sales representative about Eluvia 150.

Eluvia Data Exceptional Outcomes chart.
 
Learn More about Eluvia
 

Eluvia™ Drug-Eluting Vascular Stent System UPN and GTIN Codes

DescriptionUPNGTIN
Eluvia 6 mm x 40 mm x 130 cmH7493929460041008714729876571
Eluvia 6 mm x 60 mm x 130 cmH7493929460061008714729876588
Eluvia 6 mm x 80 mm x 130 cmH7493929460081008714729876595
Eluvia 6 mm x 100 mm x 130 cmH7493929460101008714729876601
Eluvia 6 mm x 120 mm x 130 cmH7493929460121008714729876618
Eluvia 6 mm x 150* mm x 130 cmH7493929460151008714729876625
Eluvia 7 mm x 40 mm x 130 cmH7493929470041008714729876694
Eluvia 7 mm x 60 mm x 130 cmH7493929470061008714729876700
Eluvia 7 mm x 80 mm x 130 cmH7493929470081008714729876717
Eluvia 7 mm x 100 mm x 130 cmH7493929470101008714729876724
Eluvia 7 mm x 120 mm x 130 cmH7493929470121008714729876731
Eluvia 7 mm x 150* mm x 130 cmH7493929470151008714729876748
*Available now in 150mm length. Ask your sales representative about Eluvia 150.
 

Reimbursement

As Eluvia is a new and novel technology, Boston Scientific believes that currently available C-Codes do not accurately describe it. However, the closest applicable C-Code to report the use of Eluvia is C1874, defined as “Stent, coated/covered, with delivery system." Note: Boston Scientific Corporation is not responsible for correct use of codes on submitted claims; this information does not constitute reimbursement or legal advice.
Top